Non-invasive Continuous Blood Pressure Monitoring

Samsung, Masimo, Omron Healthcare, Aktiia SA and Nanowear are among the companies associated with this field. Samsung has research linking Galaxy Watch PPG signals with central blood pressure, while Aktiia and Nanowear are connected with cuffless wearable monitoring. Company activity ranges from wearable platforms to medical monitoring, and the evidence and intended use differ across products.

Aktiia SA, Arblet Inc. and Nanowear Inc. are named startups in this field. Aktiia is associated with a wearable-and-app blood pressure platform; Arblet’s cuffless wearable has been used in studies of blood pressure variability and exercise response; Nanowear develops multiparametric wearable sensing and has evaluated an AI-enabled cuffless monitor. Their approaches and evidence differ.

The Chinese University of Hong Kong, Chinese Academy of Sciences and Korea Advanced Institute of Science and Technology are prominent research contributors. Their work includes wearable radial-artery tonometry, flexible ultrasound sensing and cuffless ultrasonic measurement of vascular diameter. University of California at San Diego and Harvard University also appear in research on wearable ultrasound and signal-based estimation.

Recorded grant funding is $4,239,540 across 9 grants since 2020. This figure refers to grants, not the broader funding-round total. The available funding entries do not identify a complete, topic-specific investment picture, so they should not be treated as the total capital raised by companies developing continuous blood pressure monitors.

Koninklijke Phillips N.V. leads the listed patent holders with 6 patents. Dickinson has 5, while California Institute of Technology, Physio-Control, Masimo, iRhythm Technologies and Stryker Corporation each have 3. These counts identify the leading holders in the provided patent-holder data, not the full patent portfolio of each organization.

No: patent activity is reported down 65.2%, with 93 patents in the stated window. The broader activity-growth figure is also negative, while publication volume grew 14.8% last year to 653 publications. That contrast points to active research alongside a weaker recent patent trend; it does not by itself establish commercial readiness or product performance.

Maturity is mixed: established finger-cuff monitoring coexists with newer wearable and cuffless methods that are still being validated. The field includes 1,314 clinical-trial records, but that total does not show that every approach has clinical validation. Recent studies continue to examine calibration, signal quality, motion effects and performance in specific patient groups.

Recent developments include Kwangwoon University’s October 2026 graph-convolutional estimation method, an August 2026 multimodal wearable study involving Emory University and collaborators, and January 2026 reports of a flexible ultrasonic sensor. Other recent research examines force sensing and waveform analysis for operating-room monitoring, as well as physiology-informed models intended to improve calibration-free estimation.

The main approaches are volume-clamp finger cuffs, pulse transit or arrival time, PPG waveform analysis, applanation tonometry and ultrasound vascular sensing. Finger cuffs track arterial volume, while optical and timing methods infer pressure from pulse signals. Tonometry measures an arterial waveform through contact, and ultrasound monitors vessel changes. Each trades measurement directness against wearability, positioning and signal robustness.

Applications include critical care and perioperative monitoring, home hypertension management, wearable and remote health, cardiovascular disease management and maternal health. Critical-care and perioperative monitoring is associated with 726 documents and 17.4% growth; cardiovascular disease management has 646 documents and 19.7% growth. Continuous readings may help identify changes that intermittent measurements miss, but use depends on validation for the setting.